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The early identification of hearing impairment allows 
for an intervention still in the “critical” and ideal period 
of hearing and language stimulation. Pediatric ototoxicity 
is a very controversial topic. There have been variable 
percentages of ototoxicity cases in children with different 
aminoglycosides antibiotics. The main pediatric groups whom 
receive aminoglycosides are newborns with severe infections 
on the neonatal ICU. Aim: to check the functional aspect of 
the cochlear external hair cells and treatment regimens used 
to treat infections during the neonatal period. Study design: 
Experimental. Materials and Methods: we studied 26 albino 
guinea pigs, through distortion product otoacoustic emissions, 
before and after the use of gentamicin. Results: in all the 
assessments, the external hair cells functional status, studied 
by means of the distortion product otoacoustic emissions, 
proved preserved. Conclusion: In the present study, we did 
not notice changes in outer hair cell function in the albino 
guinea pigs treated with gentamicin in the doses of 4 mg/Kg/
day and 2.5 mg/Kg/day every 12 hours for 10 and 14 days.
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INTRODUCTION
Hearing plays a very important role in human 
communication. Hearing losses may serve as background 
to psychosocial disorders, as the inability to understand 
spoken language may sever one’s contact with others 
and the world1.
Early identification of hearing loss cases enables 
intervention still in the ’critical period’ in time to stimu-
late language and hearing. The central auditory system’s 
maturation process occurs during the first years of life. 
Hearing experiences in this period of greater brain plas-
ticity and establishment of new neuronal connections are 
indispensable to ensure the development of both hearing 
and language2.
From the standpoint of physiology, the auditory 
reception structure is formed by support cells and hair cells 
located in the organ of Corti. The outer hair cells cannot 
receive sound stimuli, but they can contract quickly or 
slowly due to their biomechanical properties3.
Outer hair cells make up the cochlear amplifier and 
play an important role in amplifying sound signals and 
determining the function of inner hair cells, the cochlear 
reception and encoding units that play an important role 
in cochlear frequency selectivity4.
Vibratory-mechanical signals reaching the cochlea 
stimulate the outer hair cells. Such stimulation is then 
amplified towards the inner hair cells. A measurable echo 
(otoacoustic emission) is then created5.
Otoacoustic emissions (OAEs) are low-intensity 
sound signals amplified by the contraction of outer hair 
cells in the cochlea, possibly captured in the external 
acoustic meatus. They were discovered in 1978 by David 
T. Kemp, Professor of Hearing Biophysics at the London 
University College. OAEs may be categorized as: spon-
taneous - when captured at the external acoustic meatus 
in the absence of acoustic stimulation; evoked - when 
there is release of energy captured in the external acoustic 
meatus in response to acoustic stimulation. Evoked OAEs 
can be classified as transient - evoked by short broad 
specter acoustic stimulation covering a range of frequen-
cies, clicks or tone burst; distortion product - evoked by 
two pure simultaneous tones (F1 and F2) which by inter-
modulation produce a distortion product as a response 
(2F1-F2); frequency-stimulation, evoked by a continuous 
signal of low intensity in the frequency of the presented 
stimulation: these are clinically less used4.
Hearing loss may congenital or acquired and ma-
nifest itself in many different degrees and types. Among 
the causes for acquired hearing loss is the use of ototoxic 
drugs, medication that introduces adverse effects on the 
structures of the inner ear thus affecting the auditory and/
or vestibular systems.
Pediatric ototoxicity is a controversial topic. Varied 
prevalence rates have been reported for ototoxicity in chil-
dren taking various aminoglycosides such as streptomycin, 
dihydrostreptomycin, kanamycin, amikacin, and gentami-
cin, the latter being an important drug in the treatment of 
various infections caused by gram-negative bacilli6.
Gentamicin is the first aminoglycoside of choice 
because of its low cost and as it is active in most resistant 
aerobic gram-negative bacilli7. The main pediatric groups 
receiving aminoglycosides are neonates with severe in-
fection staying at the neonatal ICU6.
Aminoglycosides damage the outer hair cells by 
initially compromising the cochlear basal turn cells. The 
incidence of ototoxicity by gentamicin ranges from 6% 
to 16% 8.
Animal studies have played an essential role in 
the development of Science. Experimental research with 
animal models is important in developing new drugs, 
enhancing the knowledge on disease pathophysiological 
mechanisms, understanding treatment modes with new 
drugs, studying biologic markers, and assessing techniques 
to be applied in humans in the future9.
Expanding the knowledge on this area will enable 
health care workers to adopt procedures that look at 
maintaining the auditory integrity of their patients, con-
sequently allowing them to enjoy a better life.
This study analyzed findings from the literature 
and looked into the dosages of gentamicin applied in the 
neonatal ICU setting to verify the relationship between 
outer hair cell function and neonatal infection therapies.
MATERIALS AND METHOD
Twenty-six female, albino Guinea pigs weighing 
between 400 and 500 grams with normal Preyer reflex 
were used in this study. All animals were used in accor-
dance with the guidelines of our institution, which by 
their turn were based on the guide for the care of lab 
animals by the Institute of Laboratory Animal Resources, 
Commission on Life Sciences, National Research council, 
National Academy Press, Washington, D. C., 1996. This 
study was approved by the Animal Experimentation Ethics 
Committee under permit 073/2007.
The drug used in this study was aminoglycoside 
gentamicin (Geramicin, 60 mg/ml, Schering) by intra-
muscular administration. All animals were weighed every 
other Day to control medication dosage. Guinea pigs were 
assessed for distortion product otoacoustic emissions in a 
soundproof booth under anesthesia by ketamine (Ketamin 
50mg/ml, Cristália,) 40 mg/kg and xylazine (Dopaser 20 
mg/ml, Calier do Brasil,) 10 mg/kg, pre and post genta-
micin administration. The equipment used was the ILO 
92 CAE System Otodynamics LTD.
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Guinea pigs were divided into five groups:
• Group 1 - control group (placebo) - two subjects 
(four cochleae) given saline solution 1.0 ml every 12 hours 
by intramuscular injection for 14 days;
• Group 2: six subjects (12 cochleae) given genta-
micin 4 mg/kg/day for 10 days;
• Group 3: six subjects (12 cochleae) given genta-
micin 4 mg/kg/day for 14 days;
• Group 4: six subjects (12 cochleae) given genta-
micin 2.5 mg/kg/Day every 12 hours for 10 days;
• Group 5: six subjects (12 cochleae) given genta-
micin 2.5 mg/kg/Day every 12 hours for 14 days.
This study considered otoacoustic emissions star-
ting at 1500 Hz to assess the functional status of outer hair 
cells in the cochlear basal turn, looking at the signal/noise 
ratio of the emissions. Statistical analysis used at first the 
Shapiro-Wilk test. As the data sets did not follow a normal 
distribution pattern we opted to use non-parametric tests: 
variable dependent (Wilcoxon) and independent (Kruskal 
Wallis). Significance level was set at 5%.
RESULTS
Considering the used dosage of gentamicin of 4 
mg/Kg/Day for 10 days of consecutive treatment (group 
2), no changes were observed in the distortion product 
otoacoustic before and after treatment in qualitative 
analysis, as otoacoustic emissions were present in both 
circumstances.
Subjects on Group 3, treated with gentamicin 4 
mg/Kg/day for 14 days, did not have changes in their 
distortion product otoacoustic emissions after treatment. 
Figure 1 shows an example of present distortion product 
otoacoustic emissions before and after treatment for 
Group 3 and also observed in all other studied groups. 
Groups 4 - treated with gentamicin 5 mg/Kg/day for 10 
days - and 5 - gentamicin 2.5 mg/Kg/day every 12 hours 
by intra-peritoneal administration for 14 days, distortion 
product OAEs were present before and after treatment.
Distortion product OAEs starting at 1.5 kHz were 
deemed present, as the size of the external ear meatus 
of Guinea pigs makes it difficult for OAEs below this fre-
quency to be detected, producing responses coinciding 
with responses to noise.
In all tests the functional status of outer hair cells, 
as analyzed by distortion product OAEs, was preserved.
The non-parametric Kruskal-Wallis test was used to 
compare the signal/noise ratios before and after treatment 
with gentamicin for statistical purposes.
No statistically significant differences were found 
among groups (p>0.05). The data on the signal/noise 
ratios observed in Groups 2, 3, 4, and 5 are shown in 
Figures 2 A, B, C and D respectively.
Figure 1. Screenshot of program ILO 92 in which we can see the pre-
sence of response to distortion product otoacoustic emissions in the 
group treated with gentamicin 4 mg/Kg/day for 14 days, before (A) and 
after (B) treatment (on the day they were slaughtered).
Figure 2. A, B, C and D. Distribution of the signal/noise ratios (Y) in dB 
NPS and studied frequencies to distortion product otoacoustic emis-
sions (X) in Hz for various studied groups (2, 3, 4, and 5 respectively).
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DISCUSSION
After conducting an experiment using distortion 
product otoacoustic emissions of albino Guinea pigs 
treated with gentamicin in order to verify outer hair cell 
function, we found that the results obtained here support 
the findings of other studies carried out on the matter.
There is no doubt that highly sensitive and specific 
auditory follow-up must be adopted when there is expo-
sure to ototoxic medication. According to the author, in 
order for the pediatric population to be monitored it is 
recommended that otoacoustic emissions are used to find 
hearing disorders before the more significant frequencies 
for speech recognition are affected, thus preventing the 
occurrence of difficulties in psychosocial development 
and academic life10.
Ototoxic drugs may potentially alter cochlear bio-
mechanics and affect hearing11. OAEs are important in 
assessing outer hair cell function along the organ of Corti, 
enabling tonotopic identification of cochlear hair cell in-
juries. It is useful to monitor risk of hearing impairment12.
According to Amatuzzi et al.13, the prevalence rates 
of sensorineural hearing loss in neonates treated at inten-
sive care units ranges from 2% to 4%, or thirteen times 
greater than that of non-ICU neonates. Risk factors for 
hearing loss such as congenital infection, neonatal anoxia, 
hyperbilirubinemia and use of ototoxic drugs have been 
studied by authors such as Kountakis et al. (2002)14 and 
Hoog et al.15.
McCracken apud Matz16 looked at the ototoxic 
potential of streptomycin, kanamycin, and gentamicin in 
seven prospective studies covering over 1,300 neonates. 
Results indicated that the risk of neonates clinically deve-
loping significant hearing impairment after 3 to 7 days of 
using aminoglycosides is minimal. The abovementioned 
author concluded that aminoglycosides have been used 
with high degrees of safety and efficacy in neonates and 
children for over two decades, as also found in this study.
Agarwal et al.17 carried out a study on the neonatal 
ICU at the Cook County Children’s Hospital IL, Chicago in 
1999 and compared the pharmacokinetics of gentamicin 
4 mg/Kg single daily dose to 2.5 mg/Kg every 12 hours 
in children under 7 days old. All patients underwent 
auditory screening using an ALGO Natus device. Results 
were either Pass or Fail for each ear. Sensitivity was of 
98% and specificity of 96%. All the children underwent 
hearing acuity tests before discharge. In this study the 
authors concluded that a daily dose of 4 mg/Kg of genta-
micin presented a significantly higher, safe and consistent 
peak of blood concentration in all subjects compared to 
the scheme 2.5 mg/Kg every 12 hours.
Gentamicin arrives at the inner ear tissues after 
systemic administration in concentrations that do not 
exceed its plasmatic concentration; therefore, it is not 
actively accumulated in the inner ear. Concentrations are 
lower in the endolymph than in the perilymph. Within 
approximately 12 hours systemically administered genta-
micin reaches the cochlear fluids, taking about 24 hours 
to see its levels reduce significantly18.
The positive polarity of the endocochlear potential 
appears to favor the entry of cationic substances such as 
gentamicin in the scala media. The communication betwe-
en the vascular system and the cochlear fluids occurs from 
the spiral ligament capillary beds and the stria vascularis 
on the lateral wall of the cochlea. The scala vestibuli and 
scala tympani promptly communicate with the spaces of 
the spiral ligament, and the endolymphatic space can be 
reached through the indirect passing of cationic drugs 
from the scala vestibuli and scala tympani and directly 
via the stria vascularis19.
According to Martins20, in terms of neonatal septi-
cemia treatment duration, it is recommended that clinical 
therapy is offered for seven to fourteen days. Under the 
dosages proposed in this experiment, no significant alte-
rations were found in the signal/noise ratios of product 
distortion OAEs, nor any significant alteration in their 
amplitudes, as also seen in the literature.
The literature is still insufficient to fully explain the 
ototoxic effects drugs such as gentamicin may have on 
neonates. Pre and perinatal risk factors associated to the 
use of ototoxic medication, changes in the renal clearan-
ce, and association with multiple drugs increase the toxic 
potential of gentamicin.
Otologic research frequently requires the use of 
experimental models, principally rats and Guinea pigs due 
to ease of handling and similarities with the human ear9. 
It is important to stress that the outcome of this study is 
reserved only to the studied sample (albino Guinea pigs), 
as according to Salt21 the interpretation of experimental 
studies is often complicated by the differences in coch-
lear dimensions found between human beings and most 
experimental animals.
A vast array of experimental studies has attempted 
to find less toxic therapies and effective means to protect 
the cochlea against chemical and physical insults11. Simi-
larly to our study, safety-related aspects regarding the use 
of antibiotic therapy have also been considered.
CONCLUSION
No changes were observed in outer hair cell func-
tion of albino Guinea pigs treated with gentamicin 4 mg/
Kg/day and 2.5 mg/Kg/day every 12 hours for 10 and 
14 days.
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